About Protein tweety homolog 2
Protein tweety homolog 2 (TTYH2) is a protein
from Homo sapiens identified by UniProt accession
Q9BSA4, 534 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Protein tweety homolog 2 |
| UniProt accession | Q9BSA4 |
| Gene | TTYH2 |
| Organism | Homo sapiens |
| Length | 534 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (36)
Diseases linked to this target (Open Targets).
- protein measurement · score 0.25
- artificial cardiac pacemaker · score 0.23
- breast adenocarcinoma · score 0.16
- PHF-tau measurement · score 0.14
- DNA methylation · score 0.14
- head and neck squamous cell carcinoma · score 0.12
- deafness · score 0.06
- benign adult familial myoclonic epilepsy · score 0.04
- cancer · score 0.04
- risk-taking behaviour · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BSA4-F1 | alphafold | PREDICTED | 81.98 | — |
Amino-acid sequence (534 residues)
MQAARVDYIA PWWVVWLHSV PHVGLRLQPV NSTFSPGDES YQESLLFLGL VAAVCLGLNL IFLVAYLVCA CHCRRDDAVQ TKQHHSCCIT WTAVVAGLIC CAAVGVGFYG NSETNDGAYQ LMYSLDDANH TFSGIDALVS GTTQKMKVDL EQHLARLSEI FAARGDYLQT LKFIQQMAGS VVVQLSGLPV WREVTMELTK LSDQTGYVEY YRWLSYLLLF ILDLVICLIA CLGLAKRSKC LLASMLCCGA LSLLLSWASL AADGSAAVAT SDFCVAPDTF ILNVTEGQIS TEVTRYYLYC SQSGSSPFQQ TLTTFQRALT TMQIQVAGLL QFAVPLFSTA EEDLLAIQLL LNSSESSLHQ LTAMVDCRGL HKDYLDALAG ICYDGLQGLL YLGLFSFLAA LAFSTMICAG PRAWKHFTTR NRDYDDIDDD DPFNPQAWRM AAHSPPRGQL HSFCSYSSGL GSQTSLQPPA QTISNAPVSE YMNQAMLFGR NPRYENVPLI GRASPPPTYS PSMRATYLSV ADEHLRHYGN QFPA
Explore Protein tweety homolog 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets